Brief: Kamada Announces Receipt Of Marketing Authorization For Glassia® For Treatment Of Alpha-1 Antitrypsin Deficiency In Switzerland
16/05/2023 13:26
Kamada Ltd KMDA.TA :
* KAMADA ANNOUNCES RECEIPT OF MARKETING AUTHORIZATION FOR
GLASSIA®
FOR TREATMENT OF ALPHA-1 ANTITRYPSIN DEFICIENCY IN SWITZERLAND
Source text for Eikon: ID:nGNX2qT8qc
Further company coverage: KMDA.TA
Recent news on Kamada
See all newsBrief: Kamada Updates On Withholding Tax Procedures On Previously Announced Cash Dividend To Shareholders
Brief: Kamada Announces Planned Transition Of Chief Financial Officer
Brief: Kamada Q2 EPS USD 0.16
Brief: Kamada Announces FDA Approval Of Its New In-House Rabies Virus Neutralization Testing Laboratory
Brief: Kamada Q4 EPS USD 0.06